Millie
your market intelligence analyst
Search Results
255 results
Your search is now limited to «Sanofi» expert search.
CNBC - Business 09/24/2020 19:04
Sanofi CEO Paul Hudson told CNBC on Thursday that the pharmaceutical company is not cutting any corners in its pursuit of developing a coronavirus vaccine.
More from CNBC - Business:
The European Commission (EC) has signed an advanced purchase agreement with Sanofi and GlaxoSmithKline (GSK) for the supply of up to 300 million doses of the companies’ COVID-19 vaccine once it is approved.
More from European Pharmaceutical Review:
FiercePharmaManufacturing 09/24/2020 09:25
Regeneron and Sanofi won’t dethrone Merck in lung cancer despite strong Libtayo data: analysts.
More from FiercePharmaManufacturing:
Seeking Alpha 09/23/2020 11:00
Sanofi reports positive data for pivotal lung cancer trial Sanofi (NASDAQ:SNY) announced positive pivotal trial data for the Libtayo as a first line treatment for locally advanced or metastatic non-small cell lung cancer.
More from Seeking Alpha:
Sanofi, GSK sign agreements with Government of Canada to supply 72 million doses of adjuvanted Covid-19 vaccine.
More from Pharmaceutical Business Review:
PharmaTimes 09/23/2020 04:55
Sanofi and GlaxoSmithKline have agreed a deal with the European Commission to provide up to 300 million doses of their potential COVID-19 vaccine candidate.
More from PharmaTimes:
PharmiWeb.com 09/23/2020 04:14
Pune, Maharashtra, India, September 23 2020 (Wiredrelease) MarketResearch.Biz –:The recent report posted via MarketResearch.Biz on Dengue Vaccines market offers critical market insights in conjunction with targeted segmentation evaluation. The report examines key using elements which might be anticipated to drive the increase of the market. Global Dengue Vaccines Market Research Report offers crucial data on numerous market situations, for example, ability improvement elements, elements contr...
More from PharmiWeb.com:
MarketWatch 09/22/2020 12:53
Sanofi and GlaxoSmithKline PLC announced Tuesday that the companies have signed agreements with Canada to supply up to 72 million doses of their COVID-19 vaccine, starting in 2021. The companies had initiated a Phase 1/2 study on their vaccine candidate on Sept. 3, and expect first results in early December to support the initiation of a Phase 3 study before the end of the year. The companies said if the data is sufficient, they plan to request regulatory approval in the first half of 2021. "To address a global health crisis of this magnitude, it takes partnerships and we are grateful to Canada for its collaboration, and to [GlaxoSmithKline] for partnering with us to develop a safe and effective vaccine," said Thomas Triomphe, global head o.
More from MarketWatch:
GlobeNewswire 09/22/2020 12:30
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine Paris Stock Exchange:SAN.
More from GlobeNewswire:
Homeland Preparedness News 09/22/2020 08:00
European Union reaches agreement with Sanofi, GSK for up to 300 million doses of COVID-19 vaccine.
More from Homeland Preparedness News:
Updated Date: Tue, 22 Sep 2020 00:00:00 EDT.
More from National Library of Medicine - DailyMed Drug Label Updates (NLM):
BioPharma-Reporter 09/21/2020 05:41
Sanofi & GSK sign deal to supply EU with 300 million COVID-19 vaccine doses.
More from BioPharma-Reporter:
World Pharma News 09/18/2020 16:20
About Sanofi Sanofi is dedicated to supporting people through their health challenges.
More from World Pharma News:
Pharmafile 09/18/2020 07:17
Sanofi confirmed that these data will be submitted to regulatory authorities in the pursuit of market approval in the US and Europe.
More from Pharmafile:
ENDPOINTS 09/18/2020 06:46
Regeneron and Sanofi took another step forward in the long march towards a greatly expanded market for their late-bloomer PD-1 checkpoint Libtayo. The two occasional allies posted an objective response rate of 31% for Libtayo among 84 patients suffering from advanced cases of basal cell carcinoma at virtual ESMO. That…
More from ENDPOINTS:
Sanofi 09/18/2020 01:00
About the Sanofi Espoir Corporate Foundation Created in 2010, the Sanofi Espoir Corporate Foundation aims to reduce inequalities in health in France and internationally.
More from Sanofi:
FierceBiotech 09/17/2020 08:19
Novo, Sanofi VC units lead Lava's $83M series C to fund gamma delta T-cell trials.
More from FierceBiotech:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications